Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), ...

More women vs. men veterans with COPD received spirometry and tobacco cessation interventions, but more men received correct ...

Astegolimab met its primary endpoint in the Phase IIb ALIENTO trial with a 15.4% reduction in annualized exacerbation rate at 52 weeks, while the Phase III ARNASA study showed a 14.5% reduction and ...

Basel: Roche has announced topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) ...

Roche announces positive results from pivotal phase IIb ALIENTO & phase III ARNASA trials of astegolimab to treat COPD: Basel Tuesday, July 22, 2025, 13:00 Hrs [IST] Roche announc ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today topline results from the pivotal Phase ...

Avalyn Pharma has drawn in another fundraising round, this time a $100 million oversubscribed series D to continue developing ...